Dr. Reddy's Laboratories Limited is a fully integrated global pharmaceutical company that operates across the entire value chain, from active pharmaceutical ingredients (APIs) to finished dosage forms. The company's business model is structured around three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment, which constitutes the vast majority of its revenue, involves the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products, including branded and unbranded generics, as well as biosimilars. The PSAI segment focuses on the production of APIs and intermediates, serving both internal needs and external innovator pharmaceutical companies. Geographically, Dr. Reddy's has a diversified footprint, generating significant revenue from North America (primarily the United States), India, Russia, CIS countries, and Europe. The company maintains a strong competitive position through its robust research and development capabilities, particularly in complex generics, oncology, gastroenterology, and cardiovascular therapeutic areas. By leveraging its low-cost manufacturing base in India and strategic global partnerships, Dr. Reddy's effectively balances the production of affordable generic medicines with the development of higher-margin specialty products.
